Smoking and fibrosis risk progression: a retrospective cohort study

Around 40% of patients with chronic liver disease (CLD) have a history of tobacco smoking, but the impact of smoking on fibrosis progression remains unclear. This study investigates the association between tobacco smoking and Fibrosis-4 Index (FIB-4) risk progression high-risk FIB-4 in primary care patients with CLD. We conducted a retrospective cohort study of primary care patients with CLD and inputs for at least two separate FIB-4 calculations. Patients with an initial FIB-4 ≥3.25, or prior diagnoses of cirrhosis, hepatocellular carcinoma, or liver transplant were excluded. The primary outcome was time to FIB-4 ≥3.25, indicating a high-risk for advanced fibrosis. Tobacco smoking status (never, former, current) was the primary exposure. We used univariate and bivariate analyses to describe the cohort and unadjusted and adjusted Cox regression models to evaluate the association of tobacco smoking with time to FIB-4 ≥3.25. The cohort had 2547 patients, with 24%, 36%, and 41% identified as current, former, and never tobacco smokers, respectively. After a mean follow-up of 5.4 years, 24% of the cohort progressed to high-risk FIB-4. In unadjusted Cox models, former (HR 1.35; 95% CI 1.11–1.63) and current (HR 1.49; 95% CI 1.21–1.83) tobacco smoking were associated with an increased risk of progression to high-risk FIB-4. Current (HR 1.27; 95% CI 1.02–1.59), but not former (HR 1.18; 95% CI 0.97–1.43), tobacco smoking was significantly associated with time to a high-risk FIB-4 after adjusting for CLD etiology, cardiometabolic, and demographic variables. Current tobacco smoking is associated with progression to a FIB-4 at high-risk for advanced fibrosis in patients with CLD.

Authors

Publication Details

Journal
Figshare
Published
2026-11-16
DOI
https://doi.org/10.6084/m9.figshare.35019663
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Smoking and fibrosis risk progression: a retrospective cohort study

Andrew D. Schreiner, David Koch, Mulugeta Gebregziabher, Samantha R. Wray et al.
2 links
Figshare
Liver Disease Diagnosis and Treatment
article

Smoking and fibrosis risk progression: a retrospective cohort study

Andrew D. Schreiner, David Koch, Mulugeta Gebregziabher, Samantha R. Wray, Justin Marsden, Jingwen Zhang
article en

Abstract

Around 40% of patients with chronic liver disease (CLD) have a history of tobacco smoking, but the impact of smoking on fibrosis progression remains unclear. This study investigates the association between tobacco smoking and Fibrosis-4 Index (FIB-4) risk progression high-risk FIB-4 in primary care patients with CLD. We conducted a retrospective cohort study of primary care patients with CLD and inputs for at least two separate FIB-4 calculations. Patients with an initial FIB-4 ≥3.25, or prior diagnoses of cirrhosis, hepatocellular carcinoma, or liver transplant were excluded. The primary outcome was time to FIB-4 ≥3.25, indicating a high-risk for advanced fibrosis. Tobacco smoking status (never, former, current) was the primary exposure. We used univariate and bivariate analyses to describe the cohort and unadjusted and adjusted Cox regression models to evaluate the association of tobacco smoking with time to FIB-4 ≥3.25. The cohort had 2547 patients, with 24%, 36%, and 41% identified as current, former, and never tobacco smokers, respectively. After a mean follow-up of 5.4 years, 24% of the cohort progressed to high-risk FIB-4. In unadjusted Cox models, former (HR 1.35; 95% CI 1.11–1.63) and current (HR 1.49; 95% CI 1.21–1.83) tobacco smoking were associated with an increased risk of progression to high-risk FIB-4. Current (HR 1.27; 95% CI 1.02–1.59), but not former (HR 1.18; 95% CI 0.97–1.43), tobacco smoking was significantly associated with time to a high-risk FIB-4 after adjusting for CLD etiology, cardiometabolic, and demographic variables. Current tobacco smoking is associated with progression to a FIB-4 at high-risk for advanced fibrosis in patients with CLD.

Figshare
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon